10-KPeriod: FY2019

Guardant Health, Inc. Annual Report, Year Ended Dec 31, 2019

Filed March 2, 2020For Securities:GH

Summary

Guardant Health, Inc.'s 2019 10-K filing, as of March 2, 2020, highlights a company in a significant growth phase within the precision oncology market. The company is focused on developing and commercializing advanced cancer diagnostics, particularly through its liquid biopsy technologies. Investors should note the substantial investment in research and development (R&D) and sales and marketing as key drivers for future revenue generation, indicating a strategic emphasis on market penetration and product innovation. While revenue growth is evident, the company continues to operate at a net loss, which is typical for companies in this R&D-intensive sector. The filing underscores the potential for Guardant's technology to transform cancer detection and treatment, but also points to inherent risks related to clinical validation, regulatory approvals, market adoption, and competition.

Financial Highlights

53 data points
Beta

Revenue

$214.38M

Net Income

-$75.65M

-35.3% Net Margin

EPS (Diluted)

$-0.84

Total Assets

$962.53M

Cash & Equivalents

$143.23M

Free Cash Flow

-$65.85M

Financial Statements
Beta
Revenue$214.38M
R&D Expenses$86.29M
Operating Expenses$296.75M
Operating Income-$82.37M
Interest Expense$1.18M
Net Income-$75.65M
EPS (Basic)$-0.84
EPS (Diluted)$-0.84
Shares Outstanding (Basic)90.60M
Shares Outstanding (Diluted)90.60M

Key Highlights

  • 1Significant revenue growth in 2019, driven by increasing adoption of its Guardant360 and GuardantOMNI tests.
  • 2Continued substantial investment in Research & Development (R&D) to advance its liquid biopsy technology and expand its product pipeline, including early-stage cancer detection.
  • 3Expansion of sales and marketing infrastructure to drive market penetration and physician adoption.
  • 4Operating at a net loss, reflecting ongoing investments in growth initiatives and R&D, which is a common characteristic for companies in the pre-commercial or early commercial stages of innovative healthcare technologies.
  • 5Focus on strategic partnerships and collaborations to enhance market access and clinical utility.
  • 6Disclosure of various risk factors, including regulatory hurdles, competition from established players and emerging technologies, reimbursement challenges, and the ability to achieve commercial success for its products.

Frequently Asked Questions

Guardant Health's primary business is the development and commercialization of advanced cancer diagnostics, particularly through its proprietary liquid biopsy technology. Its competitive advantage lies in its ability to detect cancer recurrence, treatment selection, and potentially early-stage cancer through a simple blood test, offering a less invasive and more comprehensive alternative to traditional tissue biopsies.

In 2019, Guardant Health experienced strong revenue growth driven by increasing test volumes. However, the company is still operating at a net loss due to significant investments in R&D, sales, and marketing to fuel its expansion and innovation. The outlook suggests continued investment in growth, with the long-term potential tied to successful market adoption and expansion of its product offerings, particularly in areas like early cancer detection.

Key risks include regulatory approvals for new tests, reimbursement from payers, intense competition from other diagnostic companies (both established and emerging), the need for continued clinical validation of its tests, and the successful scaling of its commercial operations to meet growing demand. The transition to widespread adoption of liquid biopsy in clinical practice also presents a significant hurdle.

Guardant Health is heavily investing in R&D for early cancer detection, aiming to shift cancer diagnosis to an earlier, more treatable stage. This includes the development of tests designed to detect cancer signals in the blood before symptoms arise, which represents a significant market opportunity but also a complex scientific and clinical challenge.